Evidence map›Paper›PMID 40496621›Full record

ArticleFrontiers in oncology2025

Strategies to accelerate cervical cancer elimination in Greece: a modeling study.

Cody Palmer, Anastasios Skroumpelos, Ugne Sabale, Ilias Gountas, Georgios Trimis, Antonis Karokis, Theodoros Agorastos

Abstract read
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Cody PalmerHealth Economic and Decision Sciences, Merck & Co., Inc., Rahway, NJ, United States.
Anastasios SkroumpelosExternal Affairs, MSD, Athens, Greece.
Ugne SabaleValue & Implementation Outcomes Research, MSD, Vilnius, Lithuania.
Ilias GountasExternal Affairs, MSD, Athens, Greece.
Georgios TrimisMedical Affairs, MSD, Athens, Greece.
Antonis KarokisExternal Affairs, MSD, Athens, Greece.
Theodoros AgorastosDepartment of Obstetrics and Gynecology, Aristotle University of Thessaloniki, Thessaloniki, Greece.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Most cervical cancer cases are caused by human papillomavirus (HPV), a vaccine-preventable infection. According to the World Health Organization (WHO), both high HPV vaccination coverage and cervical cancer screening rates will accelerate the elimination of cervical cancer, a threshold defined as <4 age-standardized cases per 100,000 women. Methods: A dynamic transmission model was used to study the effect of increased HPV vaccination coverage and cervical cancer screening rates in Greece on cervical cancer incidence over a 100-year time horizon. Greek-specific or proxy data were used for both model inputs and calibration prior to the evaluation of eight different vaccination and screening scenarios. The estimated time to cervical cancer elimination and eradication in Greece was reported as the year each scenario reached <4 cases per 100,000 and <1 case per 100,000, respectively. Results: Greece reached the WHO cervical cancer elimination threshold by 2074 with a 50% HPV vaccination coverage and 50% Pap test screening rate. When HPV DNA-based methods replaced Pap tests at the same rate and HPV vaccination coverage levels, the WHO threshold was reached by 2061. Other scenarios modeled future changes in HPV DNA-based screening rates with either 50% or 90% vaccination coverage. The 75% HPV DNA-based screening with 90% vaccination coverage scenario reached the WHO threshold by 2047 and the eradication threshold before the end of the century (2096). Conclusion: If public health interventions are implemented to accelerate HPV vaccination coverage and HPV DNA-based screening adherence within the next five years, Greece can reach the WHO's cervical cancer elimination threshold by 2047 and eradicate cervical cancer before the end of the century.

Indexed as

9-valentcervical cancerGreeceHPVHPV DNAhuman papillomavirus vaccinenonavalentscreening

Identifiers

PMID40496621
PMCPMC12148835

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.